Cancer Immunology, Immunotherapy

, Volume 68, Issue 1, pp 45–56 | Cite as

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

  • Qi Jiang
  • Qiang Fu
  • Yuan Chang
  • Zheng Liu
  • Junyu Zhang
  • Le Xu
  • Yu Zhu
  • Yiwei Wang
  • Weijuan ZhangEmail author
  • Jiejie XuEmail author
Original Article



CD19+ tumor-infiltrating B-cells (CD19+ TIB) play a crucial role in tumorigenesis, but their clinical relevance in muscle-invasive bladder cancer (MIBC) remains unknown. This study aimed to investigate the prognostic value of CD19+ TIB for post-surgery survival and adjuvant chemotherapy response in MIBC.

Experimental design

We assessed TIB by immunohistochemical staining of CD19 in 246 MIBC patients from Zhongshan Hospital and Shanghai Cancer Center. We evaluated the survival benefit of platinum-based chemotherapy according to CD19+ TIB. The mechanism underlying CD19+ TIB antitumor immunity was explored through the Cancer Genome Atlas (TCGA) dataset analysis and an in vitro Ag presentation assay.


CD19+ TIB extensively infiltrated into the tumor stroma of MIBC. Adjuvant chemotherapy (ACT) led to a significantly increased benefit in the high CD19+ TIB MIBC patients (P = 0.003). In multivariate analysis, high CD19+ TIB MIBC patients had significantly longer OS with ACT in the discovery set (HR = 0.487, P = 0.038). TCGA gene expression analyses showed enrichment of adaptive immunity, T-cell-mediated immunity, and antigen-presentation signaling pathways in high CD19+ TIB MIBC patients. Moreover, CD19+ TIB co-localized with activated CD4+ TIT and expressed surface markers characteristic of antigen-presenting cells. Finally, an antigen-presentation assay demonstrated the antigen-presentation function of CD19+ TIB.


CD19+ TIB was identified as an independent prognostic factor, which could predict for post-surgery survival and platinum-based ACT benefits in MIBC. CD19+ TIB serve as antigen-presenting cells (APCs) to activate CD4+ TIT in the tumor environment of MIBC.


CD19+ TIB Muscle-invasive bladder cancer Adjuvant chemotherapy Antitumor response 



Adjuvant chemotherapy


CD19+ tumor-infiltrating B-cell(s)


Gene set enrichment analysis


Muscle-invasive bladder cancer


Radical cystectomy


The Cancer Genome Atlas


Tumor-infiltrating T-cell(s)


Tissue microarray


Author contributions

QJ, QF and YC: acquisition of data, analysis and interpretation of data, statistical analysis and drafting the manuscript. ZL, JZ, LX, YZ and YW: technical and material support. WZ and JX: study concept and design, analysis and interpretation of data, drafting the manuscript, obtained the funding and study supervision. All authors read and approved the final manuscript.


This study was funded by grants from the National Natural Science Foundation of China (81471621, 81472227, 81671628, 31770851, 81871306 and 81872082), the Shanghai Municipal Natural Science Foundation (17ZR1405100), the Shanghai Sailing Program (18YF1404500) and the Shanghai Municipal Commission of Health and Family Planning Program (20144Y0223). The study sponsors had no roles in the study design or in the collection, analysis, and interpretation of data.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval and ethical standards

This study was approved by the institutional ethical review boards of Zhongshan Hospital, Fudan University (Registration no. B2015-030) and Fudan University Shanghai Cancer Center (Registration no. 050432-4-1212B). Written informed consent approved by the institutional ethics committee was obtained from each patient.

Supplementary material

262_2018_2250_MOESM1_ESM.pdf (433 kb)
Supplementary material 1 (PDF 432 KB)


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. CrossRefGoogle Scholar
  2. 2.
    Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, Group EGW (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3: iii40–i8. CrossRefGoogle Scholar
  3. 3.
    Witjes JA, Comperat E, Cowan NC et al (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792. CrossRefGoogle Scholar
  4. 4.
    Alfred Witjes J, Lebret T, Comperat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475. CrossRefGoogle Scholar
  5. 5.
    Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D (2016) IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov 6:247–255. CrossRefGoogle Scholar
  6. 6.
    Shalapour S, Lin XJ, Bastian IN et al (2017) Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551:340–345. CrossRefGoogle Scholar
  7. 7.
    Cooper MD (2015) The early history of B cells. Nat Rev Immunol 15:191–197. CrossRefGoogle Scholar
  8. 8.
    Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL (1996) Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 156:2809–2818Google Scholar
  9. 9.
    Senovilla L, Vacchelli E, Galon J et al (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1:1323–1343. CrossRefGoogle Scholar
  10. 10.
    Inoue S, Leitner WW, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741–7747. CrossRefGoogle Scholar
  11. 11.
    Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 108:10662–10667. CrossRefGoogle Scholar
  12. 12.
    Montfort A, Pearce O, Maniati E et al (2017) A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res 23:250–262. CrossRefGoogle Scholar
  13. 13.
    Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. CrossRefGoogle Scholar
  14. 14.
    Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213. CrossRefGoogle Scholar
  15. 15.
    Ke AW, Shi GM, Zhou J et al (2009) Role of overexpression of CD151 and/or c-met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491–503. CrossRefGoogle Scholar
  16. 16.
    Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550. CrossRefGoogle Scholar
  17. 17.
    Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457. CrossRefGoogle Scholar
  18. 18.
    Murphy K, Weaver C (2016) Janeway’s immunobiology. Garland Science, London. ISBN-13: 978-0-8153-4551-0CrossRefGoogle Scholar
  19. 19.
    Qu Y, Chen L, Lowe DB, Storkus WJ, Taylor JL (2012) Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Mol Ther 20:644–651. CrossRefGoogle Scholar
  20. 20.
    Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88–97. CrossRefGoogle Scholar
  21. 21.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279. CrossRefGoogle Scholar
  22. 22.
    Leow JJ, Martin-Doyle W, Rajagopal PS et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42–54. CrossRefGoogle Scholar
  23. 23.
    Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. CrossRefGoogle Scholar
  24. 24.
    Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C (2013) B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2:e25443. CrossRefGoogle Scholar
  25. 25.
    Shi JY, Gao Q, Wang ZC et al (2013) Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res 19:5994–6005. CrossRefGoogle Scholar
  26. 26.
    DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4 + and CD8 + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184:4006–4016. CrossRefGoogle Scholar
  27. 27.
    Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059. CrossRefGoogle Scholar
  28. 28.
    Wang W, Kryczek I, Dostal L et al (2016) Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165:1092–1105. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Immunology, School of Basic Medical SciencesFudan UniversityShanghaiChina
  2. 2.Department of Biochemistry and Molecular Biology, School of Basic Medical SciencesFudan UniversityShanghaiChina
  3. 3.Department of UrologyFudan University Shanghai Cancer CenterShanghaiChina
  4. 4.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  5. 5.Department of Urology, Ruijin Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  6. 6.Department of Urology, Ninth People’s Hospital, School of MedicineShanghai Jiaotong UniversityShanghaiChina

Personalised recommendations